Receive Phase 1 data for ALXN2050
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 4 Feb 2021
- Due
- 30 Jun 2021
- Delivered
- April 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“pending the receipt of further Phase 1 data (expected in the second quarter of 2021)”
What we found
Evidence strength A What the grades mean
Alexion's filings report receipt of further Phase 1 ALXN2050 data in April 2021, within the second-quarter 2021 deadline, and resumed PNH enrollment on that basis.
-
A Alexion Pharmaceuticals 8-K filed 2021-04-30
“following the receipt of Phase 1 data that support further dose escalation in the Phase 2 study.” ✓ confirmed on the page
-
A Alexion Pharmaceuticals 10-Q filed 2021-04-30
“In April 2021, we resumed enrollment in the Phase II study of ALXN2050 monotherapy which is underway in PNH patients based on the receipt of further Phase I data.” ✓ confirmed on the page
Checked 21 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Receive
- Deliverable
- Phase 1 data for ALXN2050
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
- Conditional
- Yes
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Alexion Pharmaceuticals? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C899866-019429 · Corrections policy